Business
Aldeyra is a biotechnology company developing therapies for immune-mediated diseases, including reproxalap for dry eye disease and allergic conjunctivitis.
Aldeyra remains pre-revenue, but FY2025 net loss narrowed to $33.8M and insiders bought $118.4K.
The read at a glance✓ Audited against SEC data
- Business mix — Immune-mediated disease biotech pipelineWatch
- Revenue — No FY2025 revenue in local rowsWatch
- Cash — Cash from ops improved to -$33.3MNote
- Profitability — Net loss narrowed to $33.8MNote
- Balance sheet — Equity fell 37.7%Watch
- Insiders — 3 buys / 1 sell; $118.4K boughtOK
- Accounting — No forensic screen in bundleNote
Leadership changes
From Aldeyra Therapeutics, Inc.'s own filings, the day they're filed.
- Martin J. Joyce · member · departureeff. 2026-04-20
- Bentley University · an officer · appointment
- Darlene Deptula-Hicks · director · appointment
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-07-15
- 8-K · Company announcement2026-06-10
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Aldeyra Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.